Timberlyne Therapeutics
Latest round
- Series A
Last raised
- Jan 2025
Total raised
- $180M
Investors
- 7
About Timberlyne Therapeutics
Based in California, US, and founded in 2024 by Christian Fougner, Timberlyne Therapeutics operates as a clinical-stage biopharmaceutical company developing novel therapies for treating patients with autoimmune diseases. The firm’s lead product, CM313, is an IgG1 monoclonal antibody specifically designed to target CD38, a protein highly expressed on plasma cells and various immune cells. CM313 enhances complement-dependent cytotoxicity, allowing it to effectively modulate the immune system and potentially provide rapid and durable responses in treating conditions such as Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. This product is positioned to address significant unmet medical needs in the autoimmune disease market, with plans for further development across multiple autoimmune indications.
Who invested in Timberlyne Therapeutics
7 investors across 1 round
See all investors in Timberlyne Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 9, 2025
Amount
$180M
Investors
Questions about Timberlyne Therapeutics
Who invested in Timberlyne Therapeutics?
Timberlyne Therapeutics has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Timberlyne Therapeutics raised?
Timberlyne Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Timberlyne Therapeutics last raise money?
Timberlyne Therapeutics's most recent round on record is a Series A, in Jan 2025.
What does Timberlyne Therapeutics do?
Based in California, US, and founded in 2024 by Christian Fougner, Timberlyne Therapeutics operates as a clinical-stage biopharmaceutical company developing novel therapies for treating patients with autoimmune diseases.
Where is Timberlyne Therapeutics headquartered?
Timberlyne Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Timberlyne Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Timberlyne Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Timberlyne Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.